Research Funding 'CardioSecur trials' Accepts Applications for mHealth Projects in Cardiology

FRANKFURT AM MAIN, Germany, September 7, 2015 /PRNewswire/ --

Personal MedSystems, manufacturer of the only mobile 22-lead ECG CardioSecur, supports up to three research projects focusing on mobile Health (mHealth) in cardiology. The aim is to support studies, especially those that deal with the reduction of the burden of disease and / or an improved efficiency of disease management using mobile ECG diagnostics. The awarded proposals will receive up to ten mobile ECG devices 'CardioSecur ACTIVE' for their research. Objective of 'CardioSecur trials' is to support research in the young but fast growing sector of mHealth and leverage evidence on patient care in cardiology. Applications will be accepted until December 31st 2015. 

According to forecasts mHealth will increase rapidly especially in North America, Europe and Asia-Pacific.[1] Patients with long-term medical conditions such as ischemia, heart rhythm disorders or severe cardiac events could benefit from mobile technologies in many ways. But data on mHealth and its impact are still rare, especially when it comes to severe cardiac diseases.

For the second time the research funding 'CardioSecur trials' supports projects focusing on mobile ECG diagnostics in order to support future-oriented research. Initiator Personal MedSystems offers with CardioSecur ACTIVE a mobile technology that allows patients to independently record an ECG using a smartphone or tablet PC at any time and any place - especially when they experience symptoms. While patients get instant feedback (neutral, yellow or red) on their measurement, comprehensive data of the event is provided to their physician. Shared via secure database helpful information for diagnosis and patient management is generated.


The application form for the 'CardioSecur trials' can be downloaded on A maximum four page application, preferably electronically, is accepted until December 31st 2015.

All applicants will be informed about the results of the selection process until January 21st 2016. In spring 2016 the best projects will be published on Personal MedSystems website

[1] 'mHealth Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020'

About Personal MedSystems and CardioSecur: 

CardioSecur is a mobile ECG device of clinical grade quality for smartphones and tablets. The 22-lead mobile ECG system using only 4 electrodes enables diagnosis of ischemia and rhythm disorders. CardioSecur comes in two versions: PRO for physicians, ACTIVE for patients. The product is an innovation of Personal MedSystems GmbH, based in Frankfurt am Main, Germany. The high tech start-up company is financed by venture capital firms Seventure Partners and High Tech Gründerfonds. Personal MedSystems received the ISO 13485 certification from TüV SüD in 2011.

Further information on

Contact CardioSecur trials: 
Personal MedSystem GmbH 
Dr. Shabnam Zolfaghari 
Clinical Research Specialist 
Hansaallee 154 
60320 Frankfurt am Main 
T: +49-69-907-47-782 


Personal MedSystems GmbH

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234